Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

The Breast · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles